Ultromics Ltd. secured a strategic investment from the American Heart Association's Go Red for Women Venture Fund to advance the use of its technology to help clinicians better identify women ...

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with ...

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to ...

Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies such as tamoxifen. Recurrence is also ...

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their blood. Yet that reality is limited to ...

A team at the University of Macau aimed to develop a novel peptide targeting the tumor necrosis factor (TNF)-TNFR2 interaction as a selective regulatory T cell (Treg) stimulator. Through phage display ...

Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies. Harbour is getting about $90 million up ...

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and ...

Much has been made of the recent skyrocketing of Medicare spending on skin substitutes, but a new enforcement action by the U ...

Siemens Healthineers AG became the latest company to sign a licensing agreement with Alzpath Inc. to use its pTau217 antibody ...

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European ...

Nchroma Bio Inc. has received a certificate for clinical trial in Hong Kong to initiate a first-in-human phase I/II trial of ...